ArticleMolecular plant pathology2026
Genome-Edited Maize Expressing Two Native Genes Confers Broad-Spectrum Resistance to Northern Corn Leaf Blight.
Article in Molecular plant pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genome-Edited Maize Expressing Two Native Genes Confers Broad-Spectrum Resistance to Northern Corn Leaf Blight.Molecular plant pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Northern corn leaf blight (NCLB) can result in yield losses of up to 50% in maize. The most effective strategy for managing NCLB is the deployment of resistant hybrids. Conventional breeding methods typically require 6 or 7 backcross generations to introgress a resistance locus, often bringing along undesirable traits that reduce yield. Recent advances in genome editing offer a precise alternative, enabling the targeted incorporation of resistance genes without linkage drag. In this study, we identified an NCLB resistance gene, NLB18-R, that is allelic to Htn1 and Ht2/Ht3. Using CRISPR-Cas9, we replaced the susceptible allele (NLB18-S) with NLB18-R in an elite inbred, resulting in enhanced resistance to NCLB. In a parallel experiment, we inserted both NLB18-R and the resistance gene Ht1-R into preselected, closely linked sites on chromosome 1. Through genetic crossing, we combined these edits into a stack. The resulting genome-edited plants exhibited resistance to Setosphaeria turcica races 0, 1 and 23N. Field trials under disease-free conditions showed no significant yield differences between hybrids carrying NLB18-R, Ht1-R, or the stack compared to null and wild-type controls. These findings demonstrate that CRISPR-Cas9-mediated genome editing is a powerful tool for rapidly developing commercial-grade maize hybrids with broad-spectrum resistance to NCLB, and potentially other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.